




Supplementary Figures 1 - 205

Supplementary Figure 1 - Grading criteria for evidence




Supplementary Figure 1. Grading criteria for evidence. Associations were categorised according to pre-defined Grading of Recommendations, Assessment, Development and Evaluations (GRADE) based on previously published umbrella review studies (Kyrgiou et al., 2017; Theodoratou et al., 2014; Tsilidis et al., 2015). We additionally required studies to have 3 or more component studies due to the prevalence of associations with very small sample sizes and a new category “not significant” for those associations which were not backed by a significant effect estimate and could not be classified as “weak”.

Supplementary Figure 2 - NLR: OS in Composite endpoints






All funnel plots within Appendix 5 display the standard error of the individual studies on the Y-axis labelled "Standard Error" and the log(HR) from the random effects estimate on the X-axis labelled "Log Hazard Ratio". The pseudo 95% CI are centred around the fixed effects summary effect estimate.



All forest plots display both the weightings and summary effect size estimates for both fixed and random effects models. (ES) Effect Size, (seES) Standard error of Effect Size.

Supplementary Figure 3 - NLR: DFSin Composite endpoints (solid tumours)




Supplementary Figure 4 - NLR: PFS in Composite endpoints

Study	ES	seES	Hazard Ratio	HR	95%-CI	Weight (fixed)	Weight (random)
Berardi	0.31	0.1344		1.36	[1.04; 1.77]	1.7%	5.4%
Botta	0.69	0.3039		1.99	[1.10; 3.61]	0.3%	2.8%
Botta	0.51	0.2618		1.67	[1.00; 2.79]	0.4%	3.3%
Cetin	0.10	0.0355		1.11	[1.04; 1.19]	23.8%	6.7%
Cho	0.39	0.1248		1.48	[1.16; 1.89]	1.9%	5.5%
Chua	0.47	0.1762		1.60	[1.13; 2.26]	1.0%	4.6%
Giordano	1.17	0.3217		3.21	[1.71; 6.03]	0.3%	2.6%
Grenader	0.34	0.1080		1.40	[1.13; 1.73]	2.6%	5.8%
Grenader	0.55	0.0424		1.73	[1.59; 1.88]	16.7%	6.7%
Halazun	1.51	0.3076		4.52	[2.47; 8.26]	0.3%	2.8%
He	0.41	0.1634		1.51	[1.10; 2.08]	1.1%	4.8%
Huang	0.97	0.3708		2.63	[1.27; 5.44]	0.2%	2.2%
Jafri	0.54	0.1636		1.72	[1.25; 2.37]	1.1%	4.8%
Kaneko	0.18	0.4726		1.20	[0.48; 3.03]	0.1%	1.5%
Keizman	1.04	0.2664		2.83	[1.68; 4.77]	0.4%	3.3%
Keizman	1.26	0.3215		3.52	[1.87; 6.61]	0.3%	2.6%
Lee	0.02	0.0292		1.02	[0.96; 1.08]	35.3%	6.8%
Pinato	0.59	0.3536		1.80	[0.90; 3.60]	0.2%	2.3%
Rossi	0.41	0.1331		1.51	[1.16; 1.96]	1.7%	5.4%
Templeton	0.26	0.0627		1.30	[1.15; 1.47]	7.6%	6.5%
Wu	0.43	0.2135		1.54	[1.01; 2.34]	0.7%	4.0%
Zeng	0.58	0.1982		1.79	[1.21; 2.64]	0.8%	4.3%
Zhang	0.43	0.1435		1.54	[1.16; 2.04]	1.5%	5.2%


Pooled HR by Fixed Effects 1.25 [1.21; 1.30] 100.0% --
Pooled HR by Random Effects 1.63 [1.43; 1.86] -- 100.0%
Prediction interval [0.94; 2.81]

Heterogeneity: $I^2 = 89\%$ [84%; 92%], $\chi^2_{22} = 192.17$ ($p < 0.01$)


Tau² = 0.254





Funnel Plot with pseudo 95% Confidence Intervals





Meta-regression of effect size and NLR cut-off





Supplementary Figure 5 - IN: CSS in Composite endpoints





Supplementary Figure 6 – IN: OS in Composite endpoints




Supplementary Figure 7 – PN: OS in Composite endpoints




Supplementary Figure 8 – SN: OS in Composite endpoints






Supplementary Figure 10 - NLR: CSS in all operable cancers






Tau² = 0.262




Supplementary Figure 11 - NLR: OS in advanced cancer with immunotherapy





Supplementary Figure 12 - NLR: OS in advanced cancer with anti-VEGFR






Supplementary Figure 13 - NLR: OS with immune checkpoint inhibitors





Tau² = 0.448






Supplementary Figure 14 - NLR: PFS in advanced cancer with immunotherapy






Supplementary Figure 15 - NLR: PFS with immune checkpoint inhibitors






Supplementary Figure 16 - NLR: OS with neoadjuvant chemotherapy





Supplementary Figure 17 - NLR: RFS with neoadjuvant chemotherapy






Supplementary Figure 18 - NLR: CSS with neoadjuvant chemotherapy






Supplementary Figure 19 – IN: OS in gastric cancers





Supplementary Figure 20 - NLR: OS in gastric cancers





Supplementary Figure 21 - NLR: OS in gastric cancer with resection






Supplementary Figure 22 - NLR: OS in gastrointestinal stromal cancer






Supplementary Figure 23 - NLR: PFS in gastric cancers






Supplementary Figure 24 - NLR: DFSin gastric cancers






Supplementary Figure 25 - NLR: DFS in gastric cancers with resection




Supplementary Figure 26 - NLR: OS in colorectal cancer





Supplementary Figure 27 - NLR: DFS in colorectal cancer with palliative chemotherapy





Supplementary Figure 28 - NLR: PFS in colorectal cancer






Tau² = 0.341






Supplementary Figure 29- NLR: DFS in colorectal cancer






Supplementary Figure 30 - NLR: OS in rectal cancer






Supplementary Figure 31 - NLR: DFS in rectal cancer






Supplementary Figure 32 - NLR: RFS in rectal cancer





Supplementary Figure 33 - NLR: OS in colorectal liver metastasis






Supplementary Figure 34 - NLR: OS in colorectal liver metastasis with surgical resection






Supplementary Figure 35 - NLR: OS in colorectal liver metastasis with non-surgical treatment





Supplementary Figure 36 - NLR: RFS in colorectal liver metastasis






Supplementary Figure 37 - NLR: RFS in colorectal liver metastasis with surgical resection






Supplementary Figure 38 - NLR: RFS in colorectal liver metastasis with non-surgical treatment






Supplementary Figure 39 - NLR: OS in pancreatic cancer






Supplementary Figure 40 - NLR: OS in pancreatic cancer with resection





Supplementary Figure 41 - NLR: DFS in pancreatic cancer






Supplementary Figure 42 - NLR: CSS in pancreatic cancer






Supplementary Figure 43 - NLR: OS in gynaecologic cancer




Supplementary Figure 44 - NLR: OS in cervical cancer





Supplementary Figure 45 - NLR: PFS in cervical cancer






Supplementary Figure 46 - NLR: PFS in ovarian cancer





Tau² = 0.330





Supplementary Figure 47 - NLR: OS in breast cancer






Supplementary Figure 48 - NLR: OS in breast cancer with metastasis




Supplementary Figure 49 - NLR: OS in breast cancer without metastasis



Supplementary Figure 50 - NLR: OS in triple-negative breast cancer




Supplementary Figure 51 - NLR: DFS in breast cancer




Tau² = 0.281




Funnel Plot with pseudo 95% Confidence Intervals





Meta-regression of effect size and NLR cut-off






Supplementary Figure 52 - NLR: DFS in breast cancer with metastasis





Supplementary Figure 53 - NLR: DFS in breast cancer without metastasis





Supplementary Figure 54 - NLR: DFS in triple-negative breast cancer






Supplementary Figure 55 - NLR: CSS in breast cancer






Supplementary Figure 56 - IN: OS in hepatocellular carcinoma and cholangiocarcinoma





Supplementary Figure 57 - NLR: OS in hepatocellular carcinoma




Supplementary Figure 58 - NLR: OS in hepatocellular carcinoma with transplant





Supplementary Figure 59 - NLR: OS in hepatocellular carcinoma with radiofrequency ablation






Supplementary Figure 60 - NLR: OS in hepatocellular carcinoma with mixed treatment





Tau² = 0.84






Supplementary Figure 61 - NLR: DFS in hepatocellular carcinoma






Supplementary Figure 62 - NLR: DFS in hepatocellular carcinoma with radiofrequency ablation






Supplementary Figure 63 - NLR: RFS in hepatocellular carcinoma




Supplementary Figure 64 - NLR: RFS in hepatocellular carcinoma with transplant





Supplementary Figure 65 - NLR: RFS in hepatocellular carcinoma with resection






Supplementary Figure 66 - NLR: OS in biliary tract cancer





Tau² = 0.0950





Supplementary Figure 67 - NLR: RFS in biliary tract cancer






Supplementary Figure 68 - NLR: OS in large-B cell cancer






Supplementary Figure 69 - NLR: PFS in large-B cell cancer





Supplementary Figure 70 - NLR: OS in gastroenteropancreatic neuroendocrine tumour





Supplementary Figure 71 - NLR: RFS in gastroenteropancreatic neuroendocrine tumour





Supplementary Figure 72 - NLR: OS in pancreatic neuroendocrine tumour






Supplementary Figure 73 - NLR: RFS in pancreatic neuroendocrine tumour






Supplementary Figure 74 – IN: OS in non-small cell lung cancer






Supplementary Figure 75 - NLR: PFS in non-small cell lung cancer






Supplementary Figure 76 – NLR: OS in lung cancer





Supplementary Figure 77 – NLR: PFS in lung cancer






Supplementary Figure 78 – NLR: OS in lung cancer with surgery






Supplementary Figure 79 - IN: OS in neck and head cancers






Supplementary Figure 80 - NLR: RFS in neck and head cancers






Supplementary Figure 81 - NLR: OS in larynx cancer






Supplementary Figure 82 - NLR: PFS in nasopharyngeal cancer






Supplementary Figure 83 - NLR: CSS in nasopharyngeal cancer






Supplementary Figure 84 - NLR: OS in oral squamous cell carcinoma






Supplementary Figure 85 - NLR: DFS in oral squamous cell carcinoma






Supplementary Figure 86 - NLR: OS in malignant pleural mesothelioma





Supplementary Figure 87 - NLR: OS in melanoma




Supplementary Figure 88 - NLR: PFS in melanoma





Supplementary Figure 89 – IN: OS in renal cancer






Supplementary Figure 90 - NLR: OS in renal cancer






Tau² = 0.185






Supplementary Figure 91 - NLR: OS in advanced renal cancer






Supplementary Figure 92 - NLR: OS in localised renal cancer






Supplementary Figure 93 - NLR: OS in renal cancer with tyrosine-kinase inhibitors






Supplementary Figure 94 - NLR: RFS in renal cancer






Supplementary Figure 95 - NLR: RFS in localised renal cancer






Supplementary Figure 96 - NLR: PFS in renal cancer






Supplementary Figure 97 - NLR: PFS in advanced renal cancer






Supplementary Figure 98 - NLR: PFS in renal cancer with tyrosine-kinase inhibitors






Supplementary Figure 99 - NLR: CSS in renal cancer





Supplementary Figure 100 - NLR: RFS in urothelial carcinoma




Supplementary Figure 101 - NLR: OS in urinary cancer




Supplementary Figure 102 - NLR: RFS in upper urinary cancer




Supplementary Figure 103 - NLR: OS in bladder cancer with metastasis




Tau²= 0






Supplementary Figure 104 - NLR: PFS in bladder and upper urinary cancer





Tau² = 0.197





Supplementary Figure 105 - NLR: RFS in bladder cancer






Supplementary Figure 106 - NLR: CSS in bladder and upper urinary cancer



Supplementary Figure 107 - NLR: PFS in castration resistant prostate cancer



Supplementary Figure 108 - NLR: OS in castration resistant prostate cancer





Supplementary Figure 109 - NLR: OS in localised prostate cancer




Study	ES	seES
Sharma 2015	0.11	0.0601
Langenlehner 2015	0.77	0.3131

Pooled HR by Fixed Effects
Pooled HR by Random Effects
 Heterogeneity: $I^2 = 76\%$, $\chi^2_1 = 4.24$ ($p = 0.04$)




Tau²= 0.406






Supplementary Figure 110 - NLR: RFS in non muscle-invasive bladder cancer






Supplementary Figure 111 - NLR: PFS in non muscle-invasive bladder cancer






Supplementary Figure 112 - NLR: RFS in high risk non muscle-invasive bladder cancer






Supplementary Figure 113 - NLR: PFS in high risk non muscle-invasive bladder cancer





Supplementary Figure 114 - NLR: OS in STS





Supplementary Figure 115 - NLR: DFS in STS






Supplementary Figure 116 - NLR: OS in STS (Synovial Sarcoma)






Supplementary Figure 117 - NLR: OS in STS (Liposarcoma)






Supplementary Figure 118 - NLR: OS in Multiple Myeloma






Supplementary Figure 119 - NLR: PFS in Multiple Myeloma






Supplementary Figure 120 - NLR: OS in Nivolumab





Supplementary Figure 121 - NLR: PFS in Nivolumab




Supplementary Figure 122 - NLR: OS in Ipilimumab





Supplementary Figure 123 - NLR: PFS in Ipilimumuab




Supplementary Figure 124 - NLR: OS in Oesophageal





Tau² = 0.267






Supplementary Figure 125 - NLR: OS in Oesophageal (Surgery)






Tau² = 0.289






Supplementary Figure 126 - NLR: CSS in Oesophageal





Supplementary Figure 127 - NLR: RFS in Oesophageal






Supplementary Figure 128 - NLR: OS in Oesophageal (DCRT)




Supplementary Figure 129 - NLR: OS in Oesophageal (Neo+Surgery)





Supplementary Figure 130 - NLR: OS in Oesophageal (No Surgery)





Supplementary Figure 131 - NLR: OS in Oesophageal SCC






Tau² = 0.217






Supplementary Figure 132 - NLR: OS in Oesophageal (Surgery+/-Chemo)






Supplementary Figure 133 - NLR: DFS in Oesophageal






Supplementary Figure 134 - NLR: PFS in Oesophageal






Supplementary Figure 135 - NLR: DFS in Colorectal (SR)






Supplementary Figure 136 - NLR: OS in Colorectal (SR)






Supplementary Figure 137 - NLR: RFS in Colorectal (SR)






Supplementary Figure 138 - NLR: OS in Endometrial carcinoma






Supplementary Figure 139 - NLR: PFS in Endometrial carcinoma






Supplementary Figure 140 - NLR: DFS in Breast (Triple Negative and Her2 Positive)






Supplementary Figure 141 - NLR: OS in Breast (Triple Negative and Her2 Positive)





Supplementary Figure 142 - NLR: DFS in Breast (SR)






Supplementary Figure 143 - NLR: OS in Breast (SR)






Supplementary Figure 144 - NLR: RFS in Breast (SR)




Supplementary Figure 145 - NLR: OS in Hepatocellular (Sorfenib)





Supplementary Figure 146 - NLR: OS in Hepatocellular (TACE)




Supplementary Figure 147 - NLR: OS in Glioma





Tau² = 0.283






Supplementary Figure 148 - NLR: OS in NSCLC






Tau² = 0.207






Supplementary Figure 149 - NLR: PFS in NSCLC (Immune Checkpoint Inhibitors)






Supplementary Figure 150 - NLR: OS in NSCLC (Chemotherapy)






Supplementary Figure 151 - NLR: PFS in NSCLC (Chemotherapy)






Supplementary Figure 152 - NLR: OS in NSCLC (TT)






Supplementary Figure 153 - NLR: PFS in NSCLC (TT)






Supplementary Figure 154 - NLR: OS in NSCLC (Nivolumab)






Supplementary Figure 155 - NLR: PFS in NSCLC (Nivoumab)



Supplementary Figure 156 - NLR: OS in NSCLC (PD-1 inhibitor)



Supplementary Figure 157 - NLR: PFS in NSCLC (PD-1 inhibitor)





Supplementary Figure 158 - NLR: OS in NSCLC (ST)




Study	TE	seTE	Hazard Ratio	HR	95%-CI	Weight (fixed)	Weight (random)
Bozkaya Y 2019	0.29	0.2069		1.34	[0.89; 2.01]	0.6%	4.9%
Guo D 2019	0.67	0.2622		1.95	[1.17; 3.26]	0.4%	4.4%
Yi F 2018	1.33	0.4651		3.77	[1.52; 9.38]	0.1%	2.7%
Minami S 2018	0.31	0.3629		1.37	[0.67; 2.79]	0.2%	3.5%
Minami S2 2018	0.09	0.2502		1.09	[0.67; 1.78]	0.4%	4.5%
Xiong Y 2017	1.71	0.3174		5.54	[2.97; 10.32]	0.2%	3.9%
Shiran I 2017	0.06	0.0326		1.06	[0.99; 1.13]	23.1%	6.1%
Liu ZL 2016	0.52	0.1329		1.68	[1.29; 2.18]	1.4%	5.6%
Yao Y 2013	0.57	0.2423		1.76	[1.09; 2.83]	0.4%	4.6%
Kiriu T 2019	1.44	0.4646		4.20	[1.69; 10.44]	0.1%	2.7%
Soyano AE 2018	0.63	0.2446		1.87	[1.16; 3.02]	0.4%	4.6%
Naqash AR 2018	1.05	0.3146		2.85	[1.54; 5.28]	0.2%	3.9%
Fukui T 2019	1.43	0.5770		4.17	[1.35; 12.92]	0.1%	2.1%
Facchinetti F 2018	1.17	0.4637		3.22	[1.30; 7.99]	0.1%	2.7%
Diem S 2017	1.61	0.4611		5.01	[2.03; 12.37]	0.1%	2.7%
Bagley SJ 2017	0.73	0.2379		2.07	[1.30; 3.30]	0.4%	4.6%
Mitchell P 2015	0.11	0.0915		1.12	[0.94; 1.34]	2.9%	5.9%
Aguiar-Bujanda D 2018	1.01	0.4016		2.74	[1.25; 6.02]	0.2%	3.2%
Zhang Y 2018	0.71	0.3201		2.04	[1.09; 3.82]	0.2%	3.8%
Minami S 2017	0.07	0.0323		1.07	[1.00; 1.14]	23.5%	6.1%
Meriggi F 2017	0.99	0.4192		2.70	[1.19; 6.14]	0.1%	3.0%
Chen YM 2016	0.85	0.4111		2.35	[1.05; 5.26]	0.1%	3.1%
Berardi R 2016	0.55	0.1662		1.74	[1.26; 2.41]	0.9%	5.3%
Lee Y 2012	0.05	0.0237		1.05	[1.00; 1.10]	43.7%	6.1%

Pooled HR by Fixed Effects 1.10 [1.07; 1.14] 100.0%
Pooled HR by Random Effects 1.87 [1.53; 2.29] 100.0%
Prediction interval [0.77; 4.52]
 Heterogeneity: $I^2 = 83%$ [75%; 88%], $\chi^2_{23} = 134.01$ ($p < 0.01$)




Tau² = 0.413






Supplementary Figure 159 - NLR: PFS in NSCLC (ST)






Supplementary Figure 160 - NLR: OS in Head and Neck




Supplementary Figure 161 - NLR: PFS in Head and neck





Supplementary Figure 162 - NLR: DFS in Head and neck






Supplementary Figure 163 - NLR: OS in Head and Neck (SCC)






Tau² = 0.259






Supplementary Figure 164 - NLR: DFS in Head and Neck (SCC)






Supplementary Figure 165 - NLR: OS in Head and Neck (No Surgery)






Supplementary Figure 166 - NLR: CSS in Head and Neck (SCC)






Supplementary Figure 167 - NLR: PFS in Head and Neck (SCC)




Supplementary Figure 168 - NLR: OS in Head and Neck (SR)





Supplementary Figure 169 - NLR: OS in Hypopharynx






Supplementary Figure 170 - NLR: DFS in Larynx




Tau² = 0.022





Supplementary Figure 171 - NLR: OS in Nasopharyngeal






Supplementary Figure 172 - NLR: OS in Oral cavity





Tau² = 0.172






Supplementary Figure 173 - NLR: DFS in Oral cavity





Supplementary Figure 174 - NLR: DFS in Oropharynx






Supplementary Figure 175 - NLR: OS in Melanoma (Immune checkpoint inhibitors)





Supplementary Figure 176 - NLR: PFS in Melanoma (Immune checkpoint inhibitors)





Supplementary Figure 177 - NLR: OS in Urothelial





Supplementary Figure 178 - NLR: CSS in UTUC (Nephroureterectomy)






Supplementary Figure 179 - NLR: CSS in UTUC (Radical Cystectomy)






Supplementary Figure 180 - NLR: DFS in Urothelial






Supplementary Figure 181 - NLR: CSS in Urothelial (Radical Cystectomy)



Supplementary Figure 182 - NLR: OS in Urothelial (Radical Cystectomy)



Supplementary Figure 183 - NLR: PFS in Urothelial (Radical Cystectomy)






Supplementary Figure 184 - NLR: OS in Urothelial (Chemotherapy)



Study	TE	seTE	Hazard Ratio	HR	95%-CI	Weight (fixed)	Weight (random)
Taguchi 2015	0.40	0.1942		1.49	[1.02; 2.18]	5.5%	9.6%
Rossi 2015	0.55	0.1401		1.74	[1.32; 2.29]	10.6%	15.9%
Sonpavde 2016	0.38	0.1152		1.46	[1.16; 1.83]	15.7%	20.6%
Auvray 2016	0.25	0.0601		1.28	[1.14; 1.44]	57.6%	37.9%
Su 2017	0.46	0.1395		1.59	[1.21; 2.09]	10.7%	16.0%
Pooled HR by Fixed Effects				1.39	[1.27; 1.52]	100.0%	—
Pooled HR by Random Effects				1.45	[1.27; 1.65]	—	100.0%
Prediction interval					[1.02; 2.07]		

Heterogeneity: $I^2 = 30\%$ [0%; 73%], $\chi^2_4 = 5.69$ ($p = 0.22$)




Tau² = 0.089






Supplementary Figure 185 - NLR: PFS in Urothelial (Chemotherapy)






Supplementary Figure 186 - NLR: OS in Urothelial (Nephroureterectomy)






Supplementary Figure 187 - NLR: PFS in Urothelial (Nephroureterectomy)






Supplementary Figure 188 - NLR: PFS in Bladder (UTR)






Supplementary Figure 189 - NLR: RFS in Bladder (UTR)






Supplementary Figure 190 - NLR: OS in Bladder






Supplementary Figure 191 - NLR: OS in Bladder (Radical Cystectomy)






Supplementary Figure 192 - NLR: OS in Bladder (Radical Cystectomy and NAC)





Supplementary Figure 193 - NLR: PFS in Prostate






Supplementary Figure 194 - NLR: OS in Prostate CR(Abitaterone)




Supplementary Figure 195 - NLR: PFS in Prostate CR (Abitaterone)




Supplementary Figure 196 - NLR: OS in Prostate CR (Enzalutamide)






Supplementary Figure 197 - NLR: PFS in Prostate CR (Enzalutamide)




Tau²= 0.314





Supplementary Figure 198 - NLR: OS in Prostate (Metastatic)





Supplementary Figure 199 - NLR: DFS in Thyroid






Tau² = 0.710






Supplementary Figure 200 - NLR: OS in Ovarian





Supplementary Figure 201 - NLR: OS in Hepatocellular (SR)





Supplementary Figure 202 - NLR: DFS in Hepatocellular (SR)






Supplementary Figure 203 - NLR: OS in Prostate



Supplementary Figure 204 - NLR: RFS in Prostate Localised



Supplementary Figure 205 - NLR: OS in NSCLC (Immunotherapy)



Supplementary references

- Kyrgiou, M., Kalliala, I., Markozannes, G., Gunter, M. J., Paraskevaidis, E., Gabra, H., Martin-Hirsch, P., et al. (2017). "Adiposity and cancer at major anatomical sites: umbrella review of the literature." **BMJ** 356: j477.
- Theodoratou, E., Tzoulaki, I., Zgaga, L. and Ioannidis, J. P. (2014). "Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials." **BMJ** 348: g2035.
- Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. and Ioannidis, J. P. (2015). "Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies." **BMJ** 350: g7607.